48th week of 2009 patent applcation highlights part 29 |
Patent application number | Title | Published |
20090291037 | METHOD OF INERTISING THE IMPURITIES IN PHOSPHOGYPSUM - The invention pertains to a method of inertising free soluble impurities of phosphates and/or fluoride ions, in phosphogypsum, for use in commercial and industrial applications. The Phosphogypsum is pre-conditioned over an extended period of time separately or treated along with standard constituents by spraying, interblending or intergrinding during the process of manufacture, with alkyl, alkenyl and/or alkanol derivatives of ammonia, either individually or in combination with one another, to form stable intermediary phosphates and/or fluoride salts of the derivatives of ammonia. | 2009-11-26 |
20090291038 | Process For The Joint Production of Sodium Carbonate and Sodium Bicarbonate - Process for the joint production of sodium carbonate and sodium bicarbonate crystals, according to which:
| 2009-11-26 |
20090291039 | Process for Synthesis of Ammonia Borane for Bulk Hydrogen Storage - The present invention discloses new methods for synthesizing ammonia borane (NH | 2009-11-26 |
20090291040 | ACTIVATION METHOD FOR LITHIUM HYDRIDE, AND HYDROGEN GENERATION METHOD - A lithium hydride activation method includes: a nitrification treatment process of reacting lithium hydride with a nitride and therefore forming a chemical compound layer stable to the nitride, on a surface of the lithium hydride; and a particle size reduction process of reducing a particle size of the lithium hydride provided with the chemical compound layer by a mechanical pulverization treatment after the nitrification treatment process is performed. A hydrogen generation method includes generating hydrogen by reacting ammonia with the lithium hydride activated by the activation method. | 2009-11-26 |
20090291041 | METHODS FOR SEPERATING CARBON NANOTUBES BY ENHANCING THE DENSITY DIFFERENTIAL - A method for separating carbon nanotubes comprises: providing a mixture of carbon nanotubes; introducing an organic molecule having an end group capable of being chelated by a metal ion to the mixture of carbon nanotubes to covalently bond the organic molecule to at least one of the mixture of carbon nanotubes; and introducing a metal salt to the mixture of carbon nanotubes to chelate the end group of the organic molecule with the metal ion of the metal salt; and centrifuging the mixture of carbon nanotubes to cause the separation of the carbon nanotubes based on a density differential of the carbon nanotubes. | 2009-11-26 |
20090291042 | Continuous Method for Producing Inorganic Nanotubes - Production of nanotubes of carbon or of other inorganic material by moving a carbon-containing substrate, such as a tape or belt of carbon fibres, within a reaction chamber either though an electric arc in a gap between two electrodes or adjacent an electrode so that an electric arc exists between the electrode and the substrate, to cause the nanotubes to form on the substrate. The method enables the continuous or semi-continuous production of nanotubes. Preferably, the process is carried out at atmospheric pressure and nanotubes of high purity are produced. | 2009-11-26 |
20090291043 | PRODUCTION OF CARBON BLACK, COMPONENTS OF HYDROCARBON FUELS AND RAW MATERIAL FOR THE CHEMICAL INDUSTRY FROM RUBBER-CONTAINING WASTE - The inventive method consists in carrying out rubber crumb thermolysis in a fluidized layer in the vertical flow of a supercritical hydrocarbon alkylaromatics-containing gas. The rubber crumb thermolysis is carried out in a reactor at a mass ratio between a solvent and residues less than 0.1. The solvent is also used in the form of a fluidizing agent, a heat carrier and for removing reaction products from the reactor, thereby enabling the solvent to flow in such a way that all the products produced by the rubber crumb thermolysis are totally removed from the reactor in the main stream with the solvent. | 2009-11-26 |
20090291044 | ANATASE TYPE TiO2 NANORODS AND ITS PREPARATION METHOD - Provided is a process which includes slowly adding dropwise chilled distilled water to titanium tetrachloride to prepare solution of titanium oxychloride; adding basic solution thereto to maintain pH of the titanium oxychloride solution within a range from 3.5 to 4, thereby providing a suspension of titanium oxyhydroxide precipitate; adding basic solution thereto to adjust the suspension of titanium oxyhydroxide precipitate to be weakly basic, and heating and stirring the mixture at 80 to 100° C.; isolating and collecting dihydroxy-oxotitanium from the heated and stirred suspension of titanium oxyhydroxide precipitate, and washing it with weakly basic aqueous solution; and adding distilled water and 20 to 500 folds of hydrogen peroxide on the basis of 1 mole of Ti | 2009-11-26 |
20090291045 | Regeneration of Aluminum Hydride - The present invention provides methods and materials for the formation of hydrogen storage alanes, AlH | 2009-11-26 |
20090291046 | UNIFORMLY B-ORIENTED MFI ZEOLITE MEMBRANE WITH VARIABLE THICKNESS SUPPORTED ON SUBSTRATE AND PREPARATION METHOD THEREOF - A b-oriented MFI zeolite membrane with variable thickness is provided. The MFI zeolite membrane is composed of zeolite crystals whose b-axes are all uniformly oriented perpendicular to a substrate. Further provided is a method for preparing the MFI zeolite membrane. The method comprises forming zeolite or zeotype molecular sieve seeds with different thicknesses on a substrate and adding the seeded substrate to a gel for the synthesis of an MFI zeolite containing a structure-directing agent to grow zeolite or zeotype molecular sieve crystals thereon. The MFI zeolite membrane overcomes the limitations of prior art zeolite membranes to maximize its applicability. | 2009-11-26 |
20090291047 | Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer - The invention discloses high levels of receptors for | 2009-11-26 |
20090291048 | LEUKOCYTE-BINDING POLYPEPTIDES AND USES THEREOF - The present invention provides molecules capable of specifically binding the activated form of the beta-integrin Mac-1. The molecules may be provided in the form of peptides, polypeptides and single chained antibodies. The molecules may be used therapeutically for the treatment of disease mediated by Mac-1 (such as inflammation), or used diagnostically to locate sites of Mac-1 activity in the body. | 2009-11-26 |
20090291049 | Targeted delivery to human diseases and disorders - The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders. | 2009-11-26 |
20090291050 | PARTICULATE MATERIALS - Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles or formulations. In one embodiment, an inhaler contains an aerosol formulation containing a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm. The particles may be suspended in a nonsolvent hydrofluorocarbon fluid vehicle (e.g., HFA 134a or 227ea) at a concentration within a range from about 0.2% w/v to about 5% w/v. The formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the vehicle. The particulate active substance may contain salmeterol xinafoate, budesonide, salbutamol sulfate, dihydroergotamine mesylate, risperidone-(9-hydroxy)-palmitate, bromocriptine mesylate, or derivatives thereof. In some examples, the active substance is dihydroergotamine mesylate. | 2009-11-26 |
20090291051 | COMPOSITIONS HAVING A HEATING EFFECT - A method, including applying to a keratin substance a layer of a composition containing, in an anhydrous medium, at least one exothermic metal salt, and, optionally, one or more of the following:
| 2009-11-26 |
20090291052 | USE OF ALKYLPOLYGLYCOSIDES AS EMULSIFYING AGENTS FOR THE PREPARATION OF OIL-IN-WATER EMULSIONS COMPRISING INORGANIC FILLERS OR PIGMENTS, AND OIL-IN-WATER EMULSIONS COMPRISING SUCH ALKYLPOLYGLYCOSIDES - A composition and process of preparation of emulsifier agents based on an alkylpolyglycoside structure with a length of alkyl chain having from 6 to 12 carbon atoms to be used. The resulting emulsions exhibit an excellent dispersion of the fillers and/or pigments without it being necessary to add coemulsifier or dispersant. The emulsifier makes it possible, by itself alone, to prevent the reagglomeration of the fillers and/or pigments. | 2009-11-26 |
20090291053 | LOW MOLECULAR WEIGHT AMPHOLYTIC POLYMERS FOR PERSONAL CARE APPLICATIONS - A cosmetically acceptable composition comprising from about 0.1 to about 10 weight percent, based on polymer solids, of a water-soluble ampholyte polymer comprising: from at least 1 to as much as 95 weight percent of the nonionic monomer acrylamide; from at least 5 to as much as 80 weight percent of the cationic monomer dimethyldiallylammonium chloride; from at least 1 to as much as 75 weight percent of the anionic monomer acrylic acid, is disclosed. The application of these polymers to a keratinous substance is also disclosed. In addition, a method of treating a keratinous substance comprising applying a cosmetically acceptable composition comprising from about 0.1 to about 10 weight percent, based on polymer solids, of an ampholyte polymer produced by the following process: (1) preparing a monomer solution containing: from at least 1 to as much as 95 weight percent of the nonionic monomer acrylamide; from at least 5 to as much as 80 weight percent of the cationic monomer dimethyldiallylammonium chloride; from at least 1 to as much as 75 weight percent of the anionic monomer acrylic acid; (2) providing a reactor and water to said reactor; (3) optionally charging said reactor with a sequestering agent, a chain transfer agent or a combination thereof; (3) purging said reactor to remove oxygen from said reactor; (4) heating the contents of said reactor; and (5) feeding said monomer solution and initiator solution into said reactor, is disclosed. | 2009-11-26 |
20090291054 | METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: | 2009-11-26 |
20090291055 | METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: | 2009-11-26 |
20090291056 | Aqueous Based Cosmetic Compositions With Clear Or Translucent Non-Amidated Structuring Agent - Aqueous based compositions comprising at least one clear or translucent non-amidated structuring agent, at least one film forming polymer solubilized or dispersed in the aqueous phase, wherein the composition is substantially free of waxes. | 2009-11-26 |
20090291057 | ANIMAL CARE COMPOSITION - Methods of cleansing, conditioning and optionally therapeutically treating skin, hair, and/or other keratinous surfaces of a companion animal are provided. The method includes: contacting the skin, hair, and/or other keratinous surfaces of a companion animal with a companion animal care composition, the composition having a cleansing component, and a conditioning component; and optionally rinsing the skin, hair, and/or other keratinous surfaces of the companion animal with water; wherein after use of the composition, the composition provides a friction coefficient of from about 0.65 to about 0.8. Also included are articles of commerce having a container containing a companion animal care composition, which composition provides cleansing, conditioning, and optional treatment benefits to a companion animal. The container has instructions for cleansing, conditioning, and optionally treating the companion animal. Also included are companion animal care compositions having a cleansing component and a conditioning component, wherein after use of the composition, the composition provides a friction coefficient of from about 0.65 to about 0.8. | 2009-11-26 |
20090291058 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORGANIC SILICON COMPOUND, AT LEAST ONE CATIONIC SURFACTANT AND AT LEAST ONE ORGANIC ACID, AND METHOD FOR COSMETIC TREATMENT OF KERATINOUS FIBERS - Cosmetic composition and method for the treatment of keratinous fibres. In a cosmetically acceptable medium:
| 2009-11-26 |
20090291059 | SOAP-FREE, SELF-FOAMING GEL BASED ON N-ACYLSARCOSINE; SHAVING METHOD; CLEANSING METHOD - One subject of the invention is a soap-free, self-foaming gel comprising, in a cosmetically acceptable medium:
| 2009-11-26 |
20090291060 | Treatment of HIV - We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments. | 2009-11-26 |
20090291061 | STEM CELL THERAPY FOR BLOOD VESSEL DEGENERATION - The present disclosure provides means of treating degenerated blood vessels through administration of stem cells or activators of stem cells. In one particular embodiment vessel reactivity is increased through administration of stem cells or stem cell activating compounds. Other embodiments include “reconditioning” of vessels prone to aneurysms, repairing aneurysms of vessels, or acceleration of endothelialization after stent placement. Provided within the invention are methods of rejuvenating properties of said vessels associated with physiological health, examples of which include appropriate production of anti-coagulating/clotting factors, control of angiogenesis, and appropriate revascularization of injured tissue. | 2009-11-26 |
20090291062 | PROTEIN FORMULATIONS AND METHODS OF MAKING SAME - The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality. | 2009-11-26 |
20090291063 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL HEPATITIS - The present invention discloses a novel apathogenic viral strain useful in the treatment of viral hepatitis infections. The preferred viral strain of Infectious Bursal Disease Virus (IBDV) is specifically characterized in terms of structure and biological activities. The invention also provides recombinant IBDV viral vectors for the inclusion of exogenous nucleic acid sequences enhancing the viral replication inhibitory effect of the virus of the invention. Preferably, the viral vector comprises a nucleic acid sequence encoding a cytokine. A method of treating viral hepatitis in a host comprising administering an anti-hepatitis effective amount of the IBDV strain of the present invention also provided. | 2009-11-26 |
20090291064 | Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines - Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line and assessed for their potential application in artificial liver devices. The study included assessments of growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i.e., inducible CYP450 activity, ammonia clearance, and urea production. The PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles. PICM-19H cells display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. Ultrastructural analysis of the PICM-19B monolayers show that the roughly cuboidal cells display basal-apical polarization and are joined by tight junction-like complexes. Other ultrastructure features are similar to those of PICM-19H cells except that they possess numerous cell bodies resembling mucus vacuoles. The PICM-19B cells possess relatively high levels of GGT activity, but retain some inducible CYP450 activity, and some ammonia clearance and urea synthesis ability. These data indicate that both cell lines, either together or alone, may be useful as the cellular substrate for an artificial liver device. In vitro models of the liver are needed to replace animal models for the rapid assessment of drug biotransformation and toxicity. A unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. These cells have many activities associated with xenobiotic phase I and phase II metabolism lacking in other liver cell lines. The PICM-19H cell line was also compared to the tumor-derived human HepG2 C3A cell line and to primary cultures of adult porcine hepatocytes. The results demonstrate the potential for the use of PICM-19H cells in drug biotransformation and toxicity testing and further support their use in artificial liver device technology. | 2009-11-26 |
20090291065 | COLLECTION AND SELECTION METHODS OF AN EMBRYONIC-LIKE STEM CELL POPULATION FROM HUMAN ADULT PERIODONTAL FOLLICULAR TISSUES - Methods for the isolation, expansion and storage of a population of stem cells belonging to human dental follicles, called FENC ( | 2009-11-26 |
20090291066 | COMPOSITION AND METHOD OF TREATING FACIAL SKIN DEFECT - This invention relates to a subcutaneous deliverable composition containing an agonist of the peroxisome proliferator-activated receptor-gamma, and a method for treating facial skin defects in a mammalian subject using the subcutaneous deliverable composition. | 2009-11-26 |
20090291067 | Composition for treating cancer comprising adult stem cell culture or its fraction - The present invention provides a pharmaceutical composition for treating cancer, comprising a culture of adult stem cells or a fraction of the culture as an active ingredient. The culture of adult stem cells and its fraction, especially a specific fraction of adult stem cell culture, inhibit proliferation of a variety of cancer such as melanoma, pancreatic cancer, breast cancer, hepatic cancer, gastric cancer, colon cancer, lung cancer, and cervical cancer, thereby having excellent cancer-treating activity. The composition according to the present invention includes, not stem cells, but a complex of active proteins secreted from the stem cells, and thus both pharmaceutical problems in formulation and individual variation, which usually occurred when using stem cells, can be minimized. And also, side effects caused by direct administration of cells into the human bodies can be thoroughly prevented. | 2009-11-26 |
20090291068 | Modulation of bio-electrical rhythms via a novel engineering approach - The present invention relates to novel compositions and methods to induce, and/or modulate bio-electrical rhythms (e.g. in cardiac, neuronal and pancreatic cells) by fine-tuning the activity of HCN-encoded pacemaker channels via a novel protein- and genetic-engineering approach to augment or attenuate the associated physiological responses (e.g. heart beat, neuronal firing, insulin secretion, etc) for achieving various therapeutic purposes (e.g. sick sinus syndrome, epilepsy, neuropathic pain, diabetes, etc). | 2009-11-26 |
20090291069 | NOVEL STRAIN OF THE GENUS LACTOBACILLUS AND TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING IT - This invention relates to a novel strain of | 2009-11-26 |
20090291070 | Biologically Active Silver-Coated Proteins - Silver-coated proteins, being dissolvable or suspendable in aqueous media and/or retaining a biological activity of the protein and a process for preparing same are disclosed. Further disclosed are modified proteins which have a reducing moiety attached to the surface thereof and a process for preparing same. The modified proteins can be utilized for obtaining the silver-coated proteins. Further disclosed are a pharmaceutical composition containing and a method of treating bacterial and fungal infections utilizing biologically active silver-coated hydrogen peroxide producing enzymes such as glucose oxidase. Further disclosed are conductive elements that comprise the silver-coated proteins disclosed herein and electronic circuits containing same. Further disclosed are electrodes having the silver-coated proteins deposited thereon and biosensor systems utilizing same for determining a level of an analyte in a liquid sample. | 2009-11-26 |
20090291071 | COMPOSITIONS AND METHODS FOR CONTROLLING LIPID METABOLISM - The present invention provides a neutraceutical formulation having unexpected optimizing effects on the release of various gastric hormones and which acts unexpectedly and synergistically to inhibit various metabolic reactions such as oxidation and glycation of lipoproteins, especially LDLs. An enhancement in the release of gastric hormones optimizes the release of various gastric juices, gastric enzymes, and endocrine secretion levels of hormones that have key roles in the metabolism, digestion, assimilation of caloric and non-caloric nutrients, the storage of body fats, and appetite satiety. The present composition has further effects as an antioxidant formulation and as an enhancer and stabilizer of the activity of other antioxidants. | 2009-11-26 |
20090291072 | MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES - Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention. | 2009-11-26 |
20090291073 | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same - Compositions for treating or controlling: (i) an eye condition, disorder, or disease, or (ii) a degeneration of a component of an optic nerve system in a subject, comprise a PKC-θ inhibitor. The compositions can further include an anti-inflammatory or anti-glaucoma medicament. Such a condition or degeneration has an inflammatory component. | 2009-11-26 |
20090291074 | MUTATIONS IN OAS1 GENES - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. | 2009-11-26 |
20090291075 | BINDING AGENTS AND THEIR USE IN TARGETING TUMOR CELLS - The present invention concerns methods and compositions for administering a binding agent to a patient wherein the patient generates a response to autologous tumor. The binding agents target apoptotic tumor cells and facilitates the uptake of these apoptotic tumor cell are taken up by dendritic cells or other antigen presenting cells for processing and presentation to the immune system without the expression of circulating tumor-associated antigen (or without the need of circulating tumor antigen). | 2009-11-26 |
20090291076 | STABILIZED ANTIBODY-CONTAINING FORMULATIONS - The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof. | 2009-11-26 |
20090291077 | Antagonists of IL-6 to prevent or treat Cachexia, weakness, fatigue, and/or fever - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2009-11-26 |
20090291078 | GLYCO-ENGINEERED ANTIBODIES - The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that • the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and • at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue. | 2009-11-26 |
20090291079 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS - Compounds of formula I | 2009-11-26 |
20090291080 | LEVELS OF APRIL IN SERUM AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of APRIL in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as RA, predicting the future severity of the disease, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with APRIL antagonists, either singly or in combination with other immune suppressive drugs. | 2009-11-26 |
20090291081 | Dual-specific IL-1A/IL-1b antibodies - The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1α and human IL-1β. The dual specific antibodies of the invention also neutralize both human IL-1α and human IL-1β. The invention also provides domain antibodies (dAbs) specific for human IL-1α and human IL-1β. | 2009-11-26 |
20090291082 | Antagonists of IL-6 to raise Albumin and/or lower CRP - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. | 2009-11-26 |
20090291083 | BARB4 TARGET, ANTIBODY DESIGNATED BARB4, BARB4 RELATED ANTIBODIES, AND METHODS OF MAKING AND USING SAME - The invention provides antibodies, functional fragments, modified and variant forms, antibody targets, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment, diagnostic and vaccination methods. One treatment method includes inhibiting growth or proliferation of proliferating cells, such as hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder. | 2009-11-26 |
20090291084 | ANTI- IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2009-11-26 |
20090291085 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 2009-11-26 |
20090291086 | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia - Modified annexin proteins, including heterodimers and homodimer of various human annexins, are provided for treatment of cerebral thrombosis and global cerebral ischemia. Also provided are phosphatidylserine (PS) binding proteins for treatment of cerebral thrombosis and global cerebral ischemia. The modified annexins and/or PS binding proteins bind PS on cell surfaces, thereby preventing the attachment of leukocytes and platelets to endothelial cells during post-ischemic reperfusion. By maintaining endothelial cell and vascular wall integrity PS binding proteins and/or modified annexin proteins decrease cerebral hemorrhage. Modified annexins and other PS binding proteins also suppress the production of mediators of edema, the extension of cerebral damage during reperfusion and the risk of rethrombosis. Thus, modified annexin proteins and/or other PS binding proteins decrease brain damage following cerebral thrombosis and global cerebral ischemia. | 2009-11-26 |
20090291087 | MODULATING ANGIOGENESIS - Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye. | 2009-11-26 |
20090291088 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS - The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies. | 2009-11-26 |
20090291089 | Antagonists of IL-6 to prevent or treat Thrombosis - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. | 2009-11-26 |
20090291090 | ANTI-CD33 ANTIBODIES AND METHOD FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 2009-11-26 |
20090291091 | USE OF THE GLOBULAR DOMAIN OF ACRP30 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF THROMBOSIS-RELATED DISEASES - It is the object of the present invention to provide novel means for the treatment and/or prevention of thrombosis, tumor implantation, tumor seeding and metastasis. More specifically, the present invention relates to the use of a polypeptide comprising the globular head of Acrp30 for the manufacture of a medicament for treatment and/or prevention of thrombosis-related disorder, an hypertensive disorder of the pregnancy, tumor implantation, tumor seeding and metastasis. | 2009-11-26 |
20090291092 | TREATMENT OF MITOCHONDRIAL DISEASES WITH AN ERYTHROPOIETIN MIMETIC - Methods of treating mitochondrial disorders that are not respiratory chain disorders using compositions comprising EPO mimetic compounds or compounds capable of increasing endogenous EPO levels or stimulating erythropoiesis are disclosed. Methods of treating Friedreich's ataxia, Leigh's syndrome, or other disorders by increasing the expression of frataxin with an EPO mimetic compound or a compound capable of increasing endogenous EPO levels or stimulating erythropoiesis are also disclosed. | 2009-11-26 |
20090291093 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate. | 2009-11-26 |
20090291094 | ANTIBODIES AND PROCESSES FOR PREPARING THE SAME - Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins. | 2009-11-26 |
20090291095 | NANOEMULSION ADJUVANTS - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 2009-11-26 |
20090291096 | Methods and Apparatus for Selectively Processing Eggs Having Identified Characteristics - Methods and apparatus for processing eggs based upon a characteristic such as gender are provided. Material is extracted from each of a plurality of live eggs, the extracted material is assayed to identify eggs having the characteristic, and then eggs identified as having the characteristic are processed accordingly. | 2009-11-26 |
20090291097 | IL-17 homologous polypeptides and therapeutic uses thereof - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2009-11-26 |
20090291098 | Immunogenic LHRH compositions and methods relating thereto - The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs. | 2009-11-26 |
20090291099 | RECOMBINANT POLYPROTEIN VACCINES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple | 2009-11-26 |
20090291100 | THERAPEUTIC AGENT FOR POLYCYSTIC OVARY SYNDROME (PCOS) - A therapeutic agent for treating polycystic ovary syndrome (PCOS), which exhibits few, if any, side effects, is effective at inducing ovulation, and is safely available for not only females who desire to bear children, but also for unmarried or young females. A therapeutic agent for polycystic ovary syndrome (PCOS) in which an extract of mushrooms is contained as the active ingredient thereof is used. | 2009-11-26 |
20090291101 | Methods and compositions for treating hot flashes - Hot flashes are treated by topical application of a treatment composition including an extract of a green marine algae. A preferred green marine algae is | 2009-11-26 |
20090291102 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 2009-11-26 |
20090291103 | QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS CONTAINING SQUALENE - Measurements of the squalene content in oil-in-water emulsions can be used as a way of checking for problems during production. In particular, it has been found that a drop in squalene content can indicate that filtration problems occurred. Testing the squalene content in the final lots is easier than investigating the characteristics of the filter, and so a squalene assay simplifies the quality control of oil-in-water emulsions. | 2009-11-26 |
20090291104 | NOVEL CONOTOXIN FRAMEWORK WITH A HELIX-LOOP-HELIX FOLD - A new family Here we report a new family of four-cystine/three-loop conotoxins (designated framework 14). Three peptides of this family (flf14a-c) were isolated from the venom of | 2009-11-26 |
20090291105 | Instant Vesicular Product - A powder of reversed vesicles, which comprises one or more non-ionic surfactants and optionally a lipophilic stabilising factor and a bio-active agent, is provided. The product is prepared by making a dispersion of reversed vesicles in a suitable apolar vehicle, which vehicle is subsequently removed. In admixture with one or more excipients the product can be incorporated in compositions. | 2009-11-26 |
20090291106 | BIODEGRADABLE BLOCK COPOLYMERS WITH MODIFIABLE SURFACE - A block copolymer containing a) a hydrophobic biodegradable polymer, b) a hydrophilic polymer and c) at least one reactive group for covalent binding of a surface-modifying substance d) to the hydrophilic polymer b) is disclosed. Shaped bodies are formed to consist of the block copolymer and are utilized as carriers for tissue culture and active substances and for controlled release and targeted administration of active substances. | 2009-11-26 |
20090291107 | Chromophore Coated Metal Oxide Particles - The invention provides coated metal oxide particles, wherein metal oxide particles are coated with at least one type of crosslinkable chromophore with UV-A and/or UV-B and/or UV-C filter and/or broadband activity and optionally at least one type of crosslinkable monomer which does not have UV-A and/or UV-B and/or UV-C and/or broadband filter activity and process to obtain coated metal oxide particles and their use especially in cosmetic or dermatological formulations for the protection against harmful effects of sunlight. | 2009-11-26 |
20090291108 | Fabric with health care component - A fabric includes therapeutic members formed thereon, the therapeutic member comprising powder including Ge, GeO | 2009-11-26 |
20090291109 | Method and system for dispensing dry bird repellent - Methods and apparatus for dispensing bird repelling chemical solutions, such as a methyl anthranilate (MA) solution in a bird inhalable size, are disclosed. A small particle haze, including a bird repelling chemical, such as MA, is created in an enclosed container. The small particle haze is created by one or more venturi nozzles. The small particle haze is filtered to remove particles in excess of a predetermined size. The remaining particles are combined with a stream of air that separates the particles into a dry haze. The stream of air also directs the combination into a dispensing tube that includes a plurality of outlets for dispensing the dry haze. Relatively small diameter sized dispensing tubes are formed of a relatively rigid material such as polyvinyl chloride (PVC). Larger sized dispensing tubes are inflatable. The air added to inflate inflatable tubes further separates the dry haze particles. Filtering prevents dirt and debris from polluting the dry haze that is created through the mixture of clean dry air with the small bird repellent particles. | 2009-11-26 |
20090291110 | One swipe anti-bacteria disposable toilet seat wipe - An improved anti-bacteria wipe for cleansing and drying toilet seats in public restrooms that is biodegradable and destroys germs and bacteria on contact. The wipe is comprised of four layers. The sealing first layer in conjunction with the third layer contains the moisture of the second layer. The pre-moistened second layer is infused with a quick drying anti-bacteria solution that kills germs and bacteria on contact. The third layer is an ultra thin biodegradable plastic to prevent seepage between the second and fourth layers. The fourth layer is a dry absorbent material used to remove any remaining moisture from the toilet seat. The wipe is sealed in an outer pouch to maximize shelf life. The biodegradable wipe can easily and safely be disposed of following use with reduced environmental impact. | 2009-11-26 |
20090291111 | COATING COMPRISING AN AMORPHOUS PRIMER LAYER AND A SEMI-CRYSTALLINE RESERVOIR LAYER - The present invention provides a coating comprising a reservoir layer comprising a semi-crystalline polymer and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same. | 2009-11-26 |
20090291112 | Allograft osteochondral plug combined with cartilage particle mixture - An allograft osteochondral plug is combined with a mixture that includes freeze-milled cartilage particles, and such combination is used to repair defects in articular cartilage. The plug includes an subchondral bone portion and an integral overlying cartilage cap which is treated to remove cellular debris and proteoglycans. At least a portion of the plug has a lateral dimension selected to form an interference fit against a tissue layer exposed as a result of a bore formed in a defect area in articular cartilage of a host. The cartilage particle mixture is placed adjacent at least a portion of the plug for promoting cartilage cell migration into (i.e., from the adjacent host cartilage) and proliferation in the bore, and for enhancing tissue integration between the plug and patient (i.e., host) tissue when the plug is inserted into the bore. Methods for surgical implantation of the plug into a patient are also disclosed. | 2009-11-26 |
20090291113 | Osteogenic composition comprising a growth factor, a soluble cation salt and organic support - An open implant, and a method for preparing the implant, constituted of an osteogenic composition with at least one osteogenic growth factor, one soluble salt of a cation at least divalent, and one organic support. The organic support has no demineralized bone matrix. In one embodiment, the implant is in the form of a lyophilizate. | 2009-11-26 |
20090291114 | OSTEOGENIC COMPOSITION COMPRISING A GROWTH FACTOR/AMPHIPHILIC POLYMER COMPLEX, A SOLUBLE CATION SALT AND AN ORGANIC SUPPORT - The invention relates to an open implant constituted of an osteogenic composition comprising at least:
| 2009-11-26 |
20090291115 | Superporous hydrogel with cells encapsulated therein and method for producing the same - The present invention is a superporous hydrogel with cells encapsulated within the hydrogel matrix, and a method for producing the same. | 2009-11-26 |
20090291116 | Biocompatible and Biodegradable Porous Matrix in Particular Useful for Tissue Reconstruction - The invention mainly concerns a biocompatible and biodegradable porous matrix, characterized in that it is made of a three-block sequenced copolymer of formula (I): X G Y (I), wherein: G is a non-hydroxylated hydrophilic linear block, and X and Y represent respectively a hydrophobic linear polyester block. The invention further concerns the use of said matrix for coating tissue reconstruction after loss of substance or bioactive dressings. | 2009-11-26 |
20090291117 | FEMALE BARRIER TO PREVENT INFECTIONS FROM HUMAN IMMUNODEFICIENCY VIRUS - The Human Immunodeficiency Virus posses a significant threat to the world's population. Current strategies utilized to treat infectious agents have not been adequate to eradicate such deadly viral infections. HIV seeks out its host, a T-Helper cell, by having utilizing glycoprotein 120 probes to engage CD4 cell-surface receptors located on the surface of a T-Helper cell. Development of protective barrier techniques for women to utilize during sex that incorporate filter mediums that offer HIV virions' probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing the infectious threat of HIV. Providing barriers with filter mediums comprised of sheets, strips, or spheres of lipid bilayer or virus-like structures or hypoallergenic surfaces to carry cell-surface receptors, each type of medium having affixed cell-surface receptors intended to engage HIV virions provides an effective strategy to prevent AIDS in women. | 2009-11-26 |
20090291118 | UNIVERSAL BARRIER TO PREVENT INFECTIONS FROM HUMAN IMMUNODEFICIENCY VIRUS - The Human Immunodeficiency Virus poses a significant threat to the world's population. Current strategies to treat infectious agents have not been adequate to eradicate such deadly viral infections. HIV seeks out its host, a T-Helper cell, by utilizing glycoprotein 120 probes to engage a CD4 cell-surface receptor located on the surface of a T-Helper cell. Developing devices to offer HIV virions' probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing the infectious threat of HIV. A device in the form of a solution containing a filter medium comprised of sheets or strips or spheres of lipid bilayer or virus-like structures or hypoallergenic surfaces to carry cell-surface receptors, each type of medium having affixed to its surface cell-surface receptors intended to engage and neutralize the infectious nature of HIV virions provides an effective strategy to avert AIDS. | 2009-11-26 |
20090291119 | POLYMERIC IMPLANT AND A PROCESS FOR OBTAINING A POLYMERIC IMPLANT - The polymeric implant is obtained from a renewable source, comprising a body formed by at least one biodegradable polymer selected from the group consisting of polyhydroxyalcanoates (PHAs) and copolymers thereof, said body incorporating, in its micro-structure, an active ingredient in a sufficient quantity to control at least one oestrus cycle of mammal animals. The invention further refers to a process for obtaining a polymeric implant comprising the steps of: mixing progesterone or progestogen, at least one polymer of the group of PHAs, one polymeric additive defined by poly(ε-caprolactone), and at least one dispersant additive and/or solvent, to obtain a colloidal solution; evaporating the solvent of the colloidal solution, and forming a paste with the components dispersed therein; drying the paste to remove the residual solvents and control the granulometry of the polymer composite; extruding the polymeric composite and moulding the latter in an implant body. | 2009-11-26 |
20090291120 | Hydrophilic Polyurethane Compositions - A water-swellable linear polymer is made by reacting together a polyethylene oxide of number average molecular weight less than 4,000, an aliphatic diol, and a difunctional diisocyanate. Controlled release composition comprises the polymer together with an active agent. The polymer is able to take up pharmaceutically active agents of molecular weight 200 to 20,000. | 2009-11-26 |
20090291121 | CAPSULE AND COATED CAPSULES AS A DELIVERY SYSTEM FOR DIETARY SUPPLEMENTS AND THERAPEUTIC MATERIALS - A coated spherical capsule that comprises a seamless capsule and an edible coating is disclosed. The seamless capsule includes a seamless solid shell surrounding a mononuclear liquid or viscous core and the edible coating surrounding the seamless capsule. The edible coating can include at least one dietary supplement and at least one sugar or sugar alcohol. The liquid or viscous core can include 1-100% of a flavoring, based on total weight of the liquid or viscous core. The edible coating can include an effective amount of the at least one dietary supplement based on the weight of the edible coating. Also disclosed is a method of administering an effective amount of a dietary supplement. The method includes providing a plurality of coated spherical capsule and ingesting at least one coated spherical capsule for two or more days in order to deliver an effective amount of a dietary supplement. | 2009-11-26 |
20090291122 | Wound Care Treatment Product - The invention relates to a wound care treatment product on the basis of honey, wherein the wound care treatment product comprises raw, non-heated honey and an ozonated oil. | 2009-11-26 |
20090291124 | Functional Nano-Layered Hemostatic Material/Device - The present invention utilizes a nano-coating of an oxide such as silica, a silicate or another effective oxide on a surface to accelerate blood clotting in mammalian animals. The hemostatic layer has a thickness that is effective for the hemostasis, yet can be made thin enough to result in a resorbable film which can either be applied to a biocompatible or resorbable device that can be used in surgical applications as well as in topical applications such as trauma. | 2009-11-26 |
20090291125 | BANDAGE AND METHOD FOR VITAL BLEACHING OF SKIN - A bandage and method for vital bleaching of human skin discolored as a result of bruising (ecchymosis) provides transdermal delivery of hydrogen peroxide as a bleaching agent in gel or other form. The bandages provide delivery and application by waterproof and light-proof strips and pads carrying hydrogen peroxide in sufficient concentration for safe oxidation of bruised tissue with resultant eradication of visible discoloration, and amelioration of associated tenderness. | 2009-11-26 |
20090291126 | ADHESIVE PHARMACEUTICAL PREPARATION CONTAINING BISOPROLOL - An adhesive pharmaceutical preparation which has a less irritation to the skin surface, keeps excellent stability of bisoprolol in the preparation, and allows continuous administration of a pharmacologically effective amount of bisoprolol into the living body, is provided. The adhesive preparation | 2009-11-26 |
20090291127 | TRANSDERMAL ANTI-DEMENTIA ACTIVE AGENT FORMULATIONS AND METHODS FOR USING THE SAME - A transdermal antidementia active agent formulation is provided. In certain embodiments, the formulation includes a backing, an active agent reservoir layer including an antidementia active agent, wherein the antidementia active agent is present as both a freebase and optionally also present as a salt, an adhesive layer including the antidementia active agent, and optionally an adhesive overlay. Also provided are methods of using the formulations, e.g. for administering an antidementia active agent to a subject, and kits containing the formulations. | 2009-11-26 |
20090291128 | TRANSDERMAL DELIVERY OF CANNABINOIDS - The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ | 2009-11-26 |
20090291129 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS - The present invention provides formulations containing at least one unsaturated amphiphilic lipid and an amphipathic or hydrophobic drug and methods of making these formulations. In particular, the present invention provides formulations of at least one unsaturated phospholipid and an amphipathic or hydrophobic pyrimidine drug, methods of making these formulations and the use of such formulations in a variety of contexts, including, for example, the treatment of proliferative disorders, such as tumors and cancers. | 2009-11-26 |
20090291130 | Physiologically Active Polypeptide- or Protein-Encapsulating Polymer Micelles, and Method for Production of the Same - The invention provides a physiologically active polypeptide- or protein-encapsulating polymer micelle composition derived from a block copolymer comprising hydrophilic segments and hydrophobic segments. | 2009-11-26 |
20090291131 | SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA - The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided. | 2009-11-26 |
20090291132 | Enhanced delivery of antifungal agents - Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailability. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydrofurans in the bilayer. | 2009-11-26 |
20090291133 | METHODS AND COMPOSTIONS FOR ENHANCING TRANSDERMAL DRUG DELIVERY - Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage. | 2009-11-26 |
20090291134 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen. | 2009-11-26 |
20090291135 | Direct compression polymer tablet core - The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating. | 2009-11-26 |
20090291136 | Multiple Unit Tablets - The present invention relates to multiple unit tablets comprising multiple units compacted together with at least two tablet filler-binders and optionally other pharmaceutically acceptable excipients, wherein at least one of said tablet filler-binder is a tablet filler-binder having mean particle size-to-mean multiple unit size ratio from 10% to 40%, and at least one of said tablet filler-binder is a tablet filler-binder having mean particle size-to-mean multiple unit size ratio from 1% to 10%. | 2009-11-26 |
20090291137 | Solid oral form provided with a double release profile - The present invention relates to a solid form, intended for the administration by oral route of at least one active ingredient and capable of guaranteeing a double release mechanism of said active ingredient, the first being determined by time and the second being determined by the pH, characterized in that said active ingredient is present there in the form of a microparticle system the microparticles of which possess a core formed wholly or partly by said active ingredient and coated with at least one layer determining said release profile of said active ingredient and formed by a material composed at least (i) 25 to 75% by weight relative to the total weight of said coating of at least one polymer A which is insoluble in the gastro-intestinal fluids, (ii) 25 to 75% by weight relative to the total weight of said coating of at least one polymer B possessing a solubilization pH value comprised within the pH range from 5 to 7, and (iii) 0 to 25% by weight relative to the total weight of said coating of at least one plasticizer, said polymers A and B being present in a polymer(s) B/polymer(s) A weight ratio at least equal to 0.25 | 2009-11-26 |